BioengineeringbioRxivPreprint
Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML
J. M. Kelvin, J. Jain, A. Thapa…·E. C. Dreaden
The paper develops a nanoscale combination drug formulation targeting MERTK, FLT3, and BCL-2 to treat AML, showing improved synergistic responses in vitro and in patient samples.
DOI 10.1101/2023.03.13.531236